An inhibitor isolated from the serum-free culture medium of human myeloid leukemic HL-60 cells was able to suppress mitogen-and alloantigen-stimulated proliferative responses of normal lymphocytes in a dose-dependent manner. In vitro production, concentration, and purification by column chromatography and electrophoresis revealed that the inhibitor was produced constitutively, required RNA synthesis, and had a molecular weight in the range of 40,000-60,000. The inhibitor was also produced in vitro by myeloid leukemia cells isolated from patients with acute myelogenous leukemia. In a similar manner, the inhibitory material suppressed proliferative responses of allogeneic and autologous lymphocytes. Suppression was accompanied by drastically reduced production of interleukin 2 and lymphokines, which regulate differentiation of myeloid leukemia cells, and suppression was reversed by addition of exogenous interleukin 2. The inhibitor did not suppress clonogenic proliferation of normal granulocytes and macrophages suggesting that inhibition of production or interference with interleukin 2 activity as a possible mechanism. These interactions between leukemia cells and lymphocytes have shed new light on the immunosuppression and growth advantage of leukemia cells.
40,000-60,000. The inhibitor was also produced in vitro by myeloid leukemia cells isolated from patients with acute myelogenous leukemia. In a similar manner, the inhibitory material suppressed proliferative responses of allogeneic and autologous lymphocytes. Suppression was accompanied by drastically reduced production of interleukin 2 and lymphokines, which regulate differentiation of myeloid leukemia cells, and suppression was reversed by addition of exogenous interleukin 2. The inhibitor did not suppress clonogenic proliferation of normal granulocytes and macrophages suggesting that inhibition of production or interference with interleukin 2 activity as a possible mechanism. These interactions between leukemia cells and lymphocytes have shed new light on the immunosuppression and growth advantage of leukemia cells. Inhibitory activity of HL-60 cells was diminished after they were induced to differentiate, indicating that differentiation induced by lymphokines may be an effective means of controlling leukemia.
Disturbances in the kinetics of cellular proliferation and functions of myeloid and lymphoid cells are typical clinical features associated with acute and chronic myeloid leukemia. Evidence has been accumulating that suggests that leukemia cells or their products may be involved in the suppression of normal hematopoiesis in vivo and in vitro. The presence of leukemia cell-associated inhibitory activity in cell extracts or conditioned media (CM) has been identified by using normal granulocytes and macrophages as target cells in clonogenic agar cultures or diffusion chambers (1) (2) (3) (4) (5) . These results suggest a possible explanation for the impaired granulopoiesis often associated with leukemia. Although the role of leukemia cells or leukemia cell-associated inhibitory activity in the regulation of normal lymphocyte functions and growth remains undefined, modulation of leukemic cell differentiation has been achieved by exposure to human and murine lymphokines (6) (7) (8) . These reports suggest that lymphokines may be potentially important for the immunological surveillance over leukemias. In contrast, the effect of leukemia cells on normal lymphokine production and function has not been demonstrated. In this report we present evidence that human myeloid leukemia cells produce a distinct inhibitor that can suppress normal lymphocyte activation and lymphokine production. Included were lymphokines that are capable of inducing terminal differentiation of myeloid leukemia cells (6) (7) (8) (9) . Our results clearly show that the inhibitor can block normal lymphocyte regulation of leukemia cell differentiation, thus inhibiting immune regulatory mechanisms and leading to a tumor cell growth advantage.
MATERIALS AND METHODS
Cells and Culture Supernatants. The human leukemia HL-60 line, derived from a patient with acute promyelocytic leukemia (10) , was maintained in a serum-free defined medium described by Breitman et al. (11) . The medium contains a 1:1 mixture of Ham's F-12 and RPMI 1640 (GIBCO) supplemented with 30 nM selenium, transferrin at 5 ,ug/ml, and insulin at 5 ,ug/ml (Sigma) . Cells at approximately passage 46 were cultured initially at 2 x 105 cells per ml, and the HL-60 CM was collected from cells during the logarithmic growth phase (3-4 days). Cell-free defined medium incubated without cells for 3-4 days was used as a control. HL-60 cells were also exposed to actinomycin D at 0.1 ,ug/ml (Sigma) in culture medium for 4 hr at 37°C (12) . Cells were subsequently washed and resuspended in fresh medium, and actinomyocin D-treated HL-60 CM was collected after 3-4 days.
Isolated Inhibitor Preparation from Leukemia Cells. The serum-free culture supernatant of HL-60 cells was concentrated using a Millipore Pellicon cassette system with a PTGC membrane (molecular weight cut-off, 10 ,000) and precipitated with ammonium sulfate at 80% saturation, 4°C. The precipitate was dialyzed against 0.01 M Tris HCl, pH 8.0, and chromatographed on a DEAE-Sepharose CL-6B column with a linear 0-0.5 M NaCl gradient. The polypeptides from the active fraction were further separated by polyacrylamide gel electrophoresis using the buffer system described by Laemmli (13 Production of Differentiation-Inducing Lymphokines. The preparation of a serum-free medium with differentiationinducing lymphokines from peripheral blood lymphocytes (PBL) cultures has been reported (10, 14) . Pooled normal PBL at 1 x 106 cells per ml were cultured in RPMI 1640 with 0.2% bovine serum albumin, 1% phytohemagglutinin (PHA) (14) , and lymphocyte CM collected from 3-day cultures. The Abbreviations: CM, conditioned medium; PBL, peripheral blood lymphocytes; PHA, phytohemagglutinin; CTLL, murine cytotoxic T-cell line; IL-2, interleukin 2.
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Proc. Natl. Acad. Sci. USA 83 (1986) 3433 maturation-inducing activity present in lymphocyte CM has been shown to be derived from stimulated T cells (8) . Control lymphocyte CM used in each experiment was prepared by adding PHA to PBL from a single donor that had already been cultured for 3 days. Some PBL cultures were cultured for 3 days with additional HL-60 CM or isolated inhibitor preparation. Controls for these PBL cultures were incubated with fresh control medium or RPMI 1640 alone.
Maturation Induction of Leukemic Cells. The differentiation assay of HL-60 promyelocytes into monocytes and macrophages by the maturation-inducing activity from lymphocyte CM (6, 8, 15) was used. HL-60 cells were cultured at 0.25 x 106 cells per ml in serum-free defined medium with 20% (vol/vol) lymphocyte CM or controls. During the culture period, the acquisition of cell membrane complement receptors, phagocytic function, and the development of morphological characteristics, etc., were assessed as described (8, 9) . The cell cycle phase distribution was assayed by propidium iodine staining of DNA and analyzed on a 50H cytofluorograph (Ortho Diagnostics) (9) . A standard preparation with predetermined maturation-inducer activity was used as a reference. One unit of maturation-inducing activity is defined as the minimal amount required in a given unit volume for 5% development of mature marker-bearing cells (the mean of cells bearing complement receptor, monocyte/ macrophage morphology, and phagocytic cells) after 5 days of culture (9) . HL-60 cells after being induced for 1-4 days were washed and resuspended in fresh serum-free medium, and HL-60 CM was collected after 3-4 days.
The inhibitor preparation was evaluated for its activity on the proliferation and differentiation of normal bone marrow cells in the soft agar-gel assay (16) . The inhibitor preparation was introduced into the lower layer for stimulating 105 bone marrow cells that were seeded in the upper layer. The inhibitor or RPMI 1640 was also incorporated into the lower layer containing 106 normal leukocytes as a source of colonystimulating factor. The cultures were incubated for 20 days, and the number of colonies having more than 40 cells was recorded.
Lymphocyte Proliferative Responses. Mitogen stimulation of lymphocytes was performed in microtiter plates (Falcon) according to described procedures (17) . PBL from normal donors were isolated by Ficoll/Hypaque centrifugation (18) (Fig. 1) . Greater than 50% reduction in proliferative response was observed with the degree of inhibition proportional to the amount of HL-60 CM added (Fig. 1) . PHA responses were reduced to 30-65% of control values (5049 ± 102 cpm) when cultured with 20-50% HL-60 culture supernatant. In a similar manner, inhibitor preparations were also found to inhibit the proliferative responses to Con A or alloantigens in mixed lymphocyte cultures. Since cell counts and viability of PBL cultures were found to be unaltered by inhibitor preparations, the reduction in proliferative responses could not be attributed to cell death. To determine whether the production of inhibitory activity was linked to RNA synthesis, HL-60 cells were first treated with actinomycin D, and then the treated HL-60 CM was analyzed. As shown in Fig. 1 , the inhibitory activity for lymphocyte proliferation was not detected in these supernatants, indicating the endogenous production of the inhibitor required RNA synthesis.
Other data shown in Fig. 1 cells, CM from HL-60 cells after differentiating for 1 day or more showed no inhibitory activity. Since differentiation has been shown to be a continuous process following cellmediated interaction and since lymphocyte CM induces the majority of HL-60 cells to differentiate (8, 14) , these results suggest that cells may lose the capacity to produce inhibitory activity following initiation of differentiation.
Purification of Inihibitor and Specificity of Action. The PBL-proliferative-response inhibitor was isolated from serum-free HL-60 CM, concentrated, ammonium sulfate precipitated, and chromatographed on DEAE-Sepharose. The inhibitor activity was found only in the flow through fraction and was not retained by the column. Electrophoresis showed that this fraction contained three bands under nonreducing conditions (Fig. 2) . Eluted proteins were then tested for their effects on PBL proliferative responses to PHA. All the activity was found in fraction AIII (Fig. 2) , which had a molecular weight range of 40,000-60,000 and a single band at 58,000.
Final concentration of the inhibitor at 1-5 ag/ml resulted in minimal detectable suppression, while 20 yielded at least 50% suppression. Fig. 3A shows that only 17-25% of the control responses of PHA-stimulated PBL were obtained when the inhibitor was present. Since the inhibitor preparation was isolated from a conditioned serumfree defined medium, the medium components including insulin at 5-200/,4g/ml, transferrin at 5-500/tig/ml, or concentrated fresh defined medium were also added to PBL cultures and showed that the inhibitory effect was not due to these components of culture medium. The effect of inhibitor on the lymphocyte proliferative response can be overcome by addition of exogenous IL-2. These results of PHA responses are shown in Fig. 3B (Fig. 4A) . Fig. 4B shows that the responsiveness of CTLL cells to exogenous IL-2 was not altered in the presence of the inhibitor, indicating that the inhibitor by itself did not affect the IL-2 response. These data suggest that the lower IL-2 activity is attributable to a reduced IL-2 production.
To establish the biological specificity of the inhibitor, we next studied the effect of inhibitor (1- Effect of Inhibitor on Differentiation Inducing Lymphokines. To determine if the inhibitor has any effect on the generation of maturation-inducing lymphokines, inhibitor preparation or HL-60 CM was added to pooled PBL cultures with PHA for 3 days. The maturation-inducing activity present in these CMs was quantitated for its capacity to induce the terminal differentiation of HL-60 promyelocytes to monocytic cells. Experimental results in Table 1 indicated that there was a 93% reduction of the maturation-inducing activity in lymphocyte CM from treated PBL (9.6 units/ml) as compared to lymphocyte CM not supplemented with the inhibitor (134.6 units/ml). The activity to mediate growth cessation was reduced as measured by cell cycle analysis, and the capacity to induce mature cells with complement receptors, phagocytosis, morphological characteristics, etc., was reduced. The degree of the reduction was proportional to the amount of inhibitor added, with a minimal effect at 1 ,g/ml and a maximal effect at 20 ,g/ml or more. The effect of inhibitor in the presence of untreated lymphocyte CM was examined, and Table 1 shows that the degree of differentiation was not affected by the inhibitor. The reduction of maturation-inducing activity in the CM was, therefore, likely to be the result of suppressed production of the maturationinducing activity. The inhibitor-supplemented (20 ug/ml) PBL culture containing exogenous IL-2 at 5 units/ml yielded an increase of 40% maturation-inducing activity in this PBL CM compared to that without IL-2.
Inhibitor Activity from Patient-Derived Leukemia Cells. A preparation enriched with leukemia cells was obtained from patient RI with acute myelogenous leukemia. The preparation showed greater than 95% blasts and less than 3% T and B cells. One-day CM from these cells was added to PHAstimulated lymphocyte cultures. Both allogeneic normal PBL and the isolated autologous T cells from the same patient RI were used for PHA responses (Fig. 5) . The PHA responses were reduced significantly with the addition of the leukemia cell CM, and the degree of reduction was proportional to the amount of leukemia cell CM added. When 25% culture supernatant was used, suppression of PHA responses of allogeneic and autologous lymphocyte responses was 92% and 90%, respectively. Control CM, prepared with T cells of patient RI, did not demonstrate any inhibitory activity (Fig.  5) . Autologous cell separations were successful with a second patient with acute myelogenous leukemia, and similar results were observed.
DISCUSSION
We have presented evidence for the existence of a leukemia cell-associated inhibitor that suppresses normal lymphocyte activation and immune regulation. Serum-free HL-60 CM and a partially purified preparation of the HL-60 CM were found to inhibit significantly the proliferative response of normal lymphocytes in a dose-dependent manner. In addition, the ability of lymphocytes, exposed to the inhibitor, to generate specific lymphokines was also impaired. These lymphokines, which include y interferon (21) and the maturation inducer (9, 15) , may be components of a potential immune surveillance system over leukemia. Thus, impairment of such a regulator could provide an environment favorable for leukemia cell proliferation. While the role of these inhibitors remains to be determined, the fact that an inhibitory activity produced by leukemic cells of two patients with acute myelogenous leukemia can suppress autologous lymphocyte activation suggests a possible role in human leukemic states. Lymphocytes may function in the regulation of the differentiation ofimmature myeloid leukemia cells to mature differentiated cells, and the leukemia cell-associated inhibitor is capable of suppressing this differentiation event, shifting the balance of proliferation in favor of the leukemic state.
We (22) and others (23) have reported that some leukemia cells have the capacity to generate their own autostimulatory growth factor. The combination of autostimulatory factor and leukemia-associated inhibitor may in turn amplify the predominance of leukemia cell growth. A better understanding of such cell-mediator interactions may provide new insight for the manipulation of leukemia.
Our experiments indicate that the inhibitor blocks lymphocyte activation by suppressing IL-2 production. Reduced IL-2 production was detected in cultures exposed to inhibitor, and addition of exogenous IL-2 was able to completely abolish the inhibitory action. A similar mechanism has been described for a melanoma cell-derived inhibitor (24) . The leukemia cell inhibitor does not appear to lyse or alter the viability of myeloid or lymphoid cells, nor does it appear to directly inhibit DNA replication. Fdirthermore, the inhibitor does not aect the clonogenic proliferation and differentiation of normal granulocytes and macrophages. Gel electrophoresis of the isolated inhibitor preparation indicated a molecular weight range between 40,000-60,000 with one Mr 58,000 band. These results suggest that the leukemia cell-associated lymphocyte inhibitor may be a different molecular entity than the granulopoiesis inhibitors derived from human leukemia cells (1) (2) (3) (4) (5) . Those inhibitors were detected by their inhibition of bone marrow granulocyte and macrophage colony formation (1) (2) (3) 25) . In contrast to the lymphocyte inhibitor, whose production requires RNA synthesis, the granulocyte inhibitor is insensitive to RNA inhibition (25) . The granulocyte inhibitors have apparent molecular weights ofgreater than 300,000 or 500,000 with subunits in the range of 150,000-170,000 (2, 25, 29) . Broxmeyer et al. (25) have suggested that acidic isoferritins are the important molecules mediating the suppression of granulopoiesis. Suppressor molecules for the production of IL-2 have been described including prostaglandin E (26) , adherent cell products from leprosy patients (27) , and certain serum proteins from pregnant women (28) . Since IL-2 plays a central role in both cellular and humoral immune responses, it remains possible that the leukemia cell inhibitor could cause immune suppression at both Tand B-cell levels.
Our contention that production of the inhibitor is associated with the leukemic state is supported by two lines of evidence. First, the inhibitor was produced only by leukemia cells, not by normal lymphocytes from normal donors and by PBL from patients. Second, HL-60 cells after being induced to differentiate for 1 day or more lost their capacity to produce the inhibitor. The inability of differentiated HL-60 cells to produce the inhibitor may be associated with the early events of cellular differentiation such as the reduction of cellular RNA content (8) . Induction of the differentiation process by lymphokines may represent an effective means of controlling the production of leukemia cell-associated inhibitor. Eventually this induction process could possibly eliminate the accumulation of inhibitors and favor normal hematopoietic homeostasis.
